Transforming the Future of Hepatology (Part 2A, Breakout Session) : Observational Cohort Development Utilizing Electronic Data to Optimize Cirrhosis Outcomes
This 2-part workshop is dedicated to fostering innovation and collaboration in hepatology research. In part 1, invited talks led by top experts introduce attendees to forward-thinking perspectives on essential research aspects—including cohort design, biomarker development, and clinical trials—providing a rich base for informed conversations. Part 2 deepens the discussions in breakout sessions where experts and junior faculty jointly tackle practical issues of cohort development, biomarker development, and clinical trials. This workshop promises a stimulating environment for attendees to engage in robust discussions and learn from each other with the goal of driving improvements in hepatology research and, ultimately, patient outcomes.
Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities
George N. Ioannou, MD, FAASLD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
4:00 PM - 4:15 PM
Nov
18
2024
San Diego, CA
Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities
Giuseppe Cullaro, MD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
4:15 PM - 4:30 PM
Nov
18
2024
San Diego, CA
Strategies to Optimize Cohort Development in Patients With Cirrhosis: Innovative Approaches for Improved Care Coordination, Patient Outcomes, and Research Possibilities
Tamar Taddei, MD, MD, FAASLD, Presenter
Acute Liver Failure
Acute-on-Chronic Liver Failure
ALD
Objectives
Describe how to build a cohort for clinical research.
Identify how to leverage translational research or biomarkers to improve patient clinical outcomes in liver transplantation.
Review how to optimize study designs and endpoints, and overcome pitfalls in clinical trial design in portal hypertension.